San Mateo, CA (PRWEB) August 27, 2013
Entelos, a premier provider of physiological system modeling and services that help pharmaceutical and consumer product companies predict better paths to success, today announced that Dr. Frank Armstrong, M.D. joins the Entelos Board of Directors. Dr. Armstrong has led medical science innovation and development teams in top pharmaceutical companies and brings extensive international board experience in life science companies.
“We are very pleased to welcome Frank to the Board,” said Shawn O’Connor, CEO and President of Entelos. “Frank has worked with some of the most well-known pharmaceutical companies in the world and truly understands how our innovative solutions can support the $1.1 trillion drug industry transform from a blockbuster drug research model toward a precision medicine drug development model. Frank will be a valuable addition to the company’s Board of Directors as we begin to launch our new online software products to reach new audiences and markets”.
“I am excited to join the Board of Entelos at a time where the company is rapidly progressing on its promising goal to deliver next generation modeling products and services to its customers,” said Dr. Armstrong. “The company’s underlying science is transforming and I look forward to working with this well respected and experienced team to help shape the future success of the company.”
As an experienced, medically qualified, pharmaceutical executive Dr. Armstrong currently works as an independent advisor, consultant and Board member to life science companies. Dr. Armstrong currently serves as the Chairman of Asceneuron, Summit PLC and Xceleron Inc and as a Member of the Strategic Advisory Board of Healthcare Royalty Partners. Dr. Armstrong has extensive experience in all aspects of medical and product development in large and small companies where he has led successful product approvals for the US and EU across a range of therapeutic areas. Dr Armstrong has held senior appointments in Development at Zeneca, Bayer and Merck Serono and in addition he brings extensive experience as the CEO of several public and private biotechnology companies including CuraGen Corporation and Fulcrum Pharma, an AIM listed drug development consulting company acquired by Aptiv Solutions.
Entelos is an in silico modeling and simulation software and services company delivering predictive technologies reducing risk, time, and cost of product development for pharmaceutical, biotechnology, nutrition and consumer products customers. The Company's PhysioLab systems biology platforms generate virtual populations providing highly predictive analyses to develop safer and more effective drugs, foods and consumer products and help eliminate the need for animal testing. Entelos’ understanding of consumer variability has significant application to the emerging field of precision medicine and products. The Company is headquartered in San Mateo, California. For more information, please visit http://www.entelos.com.